Ultragenyx Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ultragenyx Pharmaceutical (RARE).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

14Buy

7Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$47Upside to Avg. PT+191.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	Joon Lee	Initiate	Neutral	$16
Sep 21, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	In-Line	$16→$18
Sep 21, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$32→$35
Sep 18, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Equal-Weight	$18→$20
Sep 18, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$31→$32
Sep 18, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$37→$39
Sep 18, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$33→$39
Sep 17, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$28→$31
Sep 4, 2026	Goldman Sachs	Salveen Richter	PT Cut	Neutral	$28→$19
Sep 4, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$43→$32
Sep 3, 2026	JP Morgan	Anupam Rama	Downgrade	Overweight→Neutral	$80→$36
Sep 3, 2026	Jefferies	Maury Raycroft	PT Cut	Buy	$77→$28
Sep 3, 2026	William Blair	Sami Corwin	Downgrade	Outperform→Market Perform	—
Sep 3, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$58→$28
Sep 3, 2026	TD Cowen	Yaron Werber	PT Cut	Buy	$49→$18
Sep 3, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$50→$18
Sep 3, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$83→$37
Sep 3, 2026	Wedbush	Laura Chico	PT Cut	Neutral	$30→$23
Sep 3, 2026	Evercore ISI Group	Liisa Bayko	Downgrade	Outperform→In-Line	$34→$16
Sep 3, 2026	Baird	Joel Beatty	Downgrade	Outperform→Neutral	$40→$16

Analyst Ratings News

PRO
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equal-Weight and raises the price target from $18 to $20.

Benzinga Newsdesk

Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.

Vandana Singh

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $37 to $39.

Benzinga Newsdesk

Ultragenyx Pharmaceutical Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ultragenyx Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

PRO
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39

People Also Watch

People Also Watch

Ultragenyx Pharmaceutical Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ultragenyx Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

PROEvercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

PROBarclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

PROMorgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

PROCanaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

PRO
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39